TrialSage Study Design Summary - study_design_2024_phase2

Indication

Obesity

Phase

Phase 2

Recommended Primary Endpoint

BMI reduction >=5% at 24 weeks

Historical Success Rate

62%

Recommended Sample Size

250 per arm

Dropout Risk

Moderate (18%)

Regulatory Precedent

EMA-approved in 3 obesity trials since 2022

Top Matched Trials

NCT01234567 - Success - 300 patients - BMI reduction

NCT02345678 - Failed - 150 patients - Weight loss %

NCT03456789 - Success - 260 patients - BMI + quality of life